(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/161387 Al 21 September 2017 (21.09.2017) P O P C T (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 36/00 (2006.01) A61P 3/00 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, A61K 36/324 (2006.01) A61P 33/02 (2006.01) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, A61K 36/752 (2006.01) C12N 5/00 (2006.01) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, A61K 47/08 (2006.01) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (21) International Application Number: TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, PCT/US20 17/033234 ZA, ZM, ZW. (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 18 May 2017 (18.05.2017) kind of regional protection available): ARIPO (BW, GH, (25) Filing Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (26) Publication Language: English TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (30) Priority Data: DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 62/390,081 18 March 2016 (18.03.2016) LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 62/390,438 29 March 2016 (29.03.2016) SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (72) Inventor; and (71) Applicant : RED), Christopher, Brian [US/US]; 880 N. Published: Alameda Street, Apt. 312, Los Angeles, CA 90012 (US). — with international search report (Art. 21(3)) (72) Inventor: COLLINS, Que, T.; 2901 Wilshire Blvd., Suite — before the expiration of the time limit for amending the #206, Santa Monica, CA 90403 (US). claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, — with information concerning request for restoration of the AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, right of priority in respect of one or more priority claims BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (Rules 26bis.3 and 48.2(b)(vii)) (54) Title: COMPOSITIONS OF NATURAL EXTRACTS AND USE THEREOF IN METHODS FOR PREVENTING OR TREATING DISEASES (57) Abstract: Synthetic drug development is slow and costly, often running into the billions of dollars. While the benefits of various abundant r and inexpensive natural products, including nat ural oils and extracts, have been postulated and speculated upon for centuries, there has been very little success in achieving national approval (e.g. FDA approval) of natural compounds so that they can be used to benefit animals and patients. As many natural products are often complex and het erogenous, appropriate technologies for rapidly and efficiently predicting efficacy and toxicity of such natural compounds has been sorely lacking. Thus, there has been a long held and still unmet need to determine and teach appropriate health, veterinary, and medical uses for an orange, frankincense and cannabis products in a costef- fective and efficient manner. Accordingly, the present invention teaches compositions, manufac 00 ture, products, and methods of use, prevention and treatment using at least one extract selected from the group comprising orange, frankincense, cannabis or other natural oil or extract or at least Fig. 1 one substance or compound isolated from said at least one oil or extract (e.g. a cannabinoid, ses o quiterpene, monoterpene, an ester, ether, alde hyde, phenylpropene, alcohol, ketone, phenol, etc.), so as to benefit medicine, human health and veterinary care. For example, the present invention teaches, the use of at least one extract selected from the group comprising orange, frankincense, cannabis or other o natural oil or extract or at least one substance or compound isolated from said at least one oil or extract to reduce miR21 expression and thus treat/prevent cancer and psoriasis. Compositions of natural extracts and use thereof in methods for preventing or treating diseases CROSS REFERENCE TO RELATED APPLICATION This application claims priority to U.S. Provisional Patent Application No. 62/390,081, filed March 18, 2016, and U.S. Provisional Patent Application No. 62/390,438, filed June 10, 2016 March 29, 2016, the disclosures of which are hereby incorporated by reference in their entirety for all purposes. FIELD OF THE INVENTION The invention relates to compositions and methods for treating or preventing diseases using natural extracts, their derivatives, or their components. BACKGROUND OF THE INVENTION In industrialized countries, cancer and metabolic diseases represent major causes of morbidity and mortality. Recent studies have demonstrated numerous molecular targets for the prevention and/or treatment of cancer and psoriasis. One such target is microRNA-21 (miR21). As most of the targets of miR-21 are tumor suppressors, miR-21 is associated with a wide variety of cancers including that of breast, ovaries, cervix, colon, lung, liver, brain, esophagus, prostate, pancreas, and thyroid. Also in a genome-wide screen, it was found deregulation of microRNA expression in psoriasis skin. miR-21 is one of the microRNAs significantly up-regulated in psoriasis skin lesions. A 2014 meta-analysis of 36 studies evaluated circulating miR-21 as a biomarker of various carcinomas, finding it has potential as a tool for early diagnosis. miR-21 is one of the most frequently upregulated miRNAs in solid tumours, and its high levels were first described in B cell lymphomas. Overall, miR-21 is considered to be a typical Onco-miR, which acts by inhibiting the expression of phosphatases, which limit the activity of signalling pathways such as AKT and MAPK. miR-21 can be transcriptionally activated by NF-κΒ and downregulate phosphatases PDCD4 and PTEN. From the prior art it is known synthetic drugs for treatment of a diseases associated with miR-21 expression. But synthetic drug development is slow and costly, often running into the billions of dollars. While the benefits of various abundant and inexpensive natural products, including natural oils and extracts, have been postulated and speculated upon for centuries, there has been very little success in achieving national approval (e.g. FDA approval) of natural compounds so that they can be used to benefit animals and patients. As many natural products are often complex and heterogenous, appropriate technologies for rapidly and efficiently predicting efficacy and toxicity of such natural compounds has been sorely lacking. Thus, there has been a long held and still unmet need to apply advanced and costly methods, such as gene array, to determine such efficacy and toxicity and teach appropriate health, veterinary, and medical uses for an orange, frankincense, cannabis, etc. products in a cost effective and efficient manner. SUMMARY OF THE INVENTION Virtually all patients could benefit from novel, efficacious drug compositions. The present invention provides novel orange, frankincense, cannabis and other natural oil and extract related compositions and inexpensive drug compositions for preventing and/or treating various conditions, diseases, and maladies especially metabolic diseases and disorders, cancer, psoriasis and improving health and well-being in general. The present invention also provides corresponding methods for producing such compositions and methods of preventing a condition, disorder or disease and treating a condition, disorder or disease in an animal or human, wherein the compositions, manufacture, or products of the present invention are provided to said animal or human. In a first aspect, according to the present invention, the problem of the prior art is solved by a composition for reducing miR-21 expression in a cell or tissue of a subject comprising deuterium depleted water (DDW) and/or at least one oil or extract selected from the group comprising orange, frankincense, cannabis or other natural oil or extract or at least one substance or compound isolated from said at least one oil or extract. The composition may further comprise at least one carrier and/or at least one excipient, wherein said composition is used for treatment of a disease associated with miR-21 expression. In a second aspect, this invention relates to a method for reducing mir-21 and other oncogene expression in a cell or tissue of a subject comprising administering to the subject a composition comprising deuterium depleted water (DDW) and/or at least one oil or extract selected from the group comprising orange, frankincense, cannabis or other natural oil or extract or at least one substance or compound isolated from said at least one oil or extract. The composition may further comprise at least one carrier and/or at least one excipient, wherein the method is for treatment of a disease associated with mir-21 and/or other oncogene expression. The method of suppressing miR21 can be seen as a method of treating and/or preventing cancer, psoriasis, and or any other disease associated with miR-21 and/or other oncogene expression. The method may be accomplished by administering to the subject an appropriate amount of composition comprising deuterium depleted water (DDW) and/or at least one oil or extract selected from the group comprising orange, frankincense, cannabis or other natural oil or extract or at least one substance or compound isolated from said at least one oil or extract, which showing potent miR21 suppression in vitro and in vivo or at least one substance or compound with miR21 suppressive activity that are isolated from such extracts.